Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2336972 | 0.90 | PTGDR2 (0.51) | PTGDR2HSD11B1CCR3 | |
| SCHEMBL2333636 | 0.87 | PTGDR2 (0.47) | PTGDR2HSD11B1 | |
| SCHEMBL2336332 | 0.86 | HSD11B1 (0.47) | PTGDR2HSD11B1 | |
| SCHEMBL2335282 | 0.86 | PTGDR2 (0.51) | PTGDR2 | |
| SCHEMBL2336069 | 0.85 | PTGDR2 (0.47) | PTGDR2CCR3 | |
| SCHEMBL2336150 | 0.84 | PTGDR2 (0.48) | PTGDR2 | |
| SCHEMBL2334698 | 0.84 | PTGDR2 (0.48) | PTGDR2HSD11B1 | |
| SCHEMBL2330653 | 0.83 | PTGDR2 (0.47) | PTGDR2 | |
| SCHEMBL2336078 | 0.83 | PTGDR2 (0.50) | PTGDR2CCR3 | |
| SCHEMBL16474072 | 0.82 | PTGDR2 (0.50) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188090-B2 | Naphthylacetic acids | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | claimed |
| US-20100125061-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-05-20 | — | — | US | claimed |
| EP-2358677-B1 | NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| EP-2358677-B1 | NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8188090-B2 | Naphthylacetic acids | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188090-B2 | Naphthylacetic acids | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188090-B2 | Naphthylacetic acids | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2358677-A1 | NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| US-20100125061-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-05-20 | — | — | US | disclosed |
| US-20100125061-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-05-20 | — | — | US | disclosed |
| US-20100125061-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-05-20 | — | — | US | disclosed |
| WO-2010055006-A1 | NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055006-A1 | NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125061-A1 | NAPHTHYLACETIC ACIDS | HRH2, HRH1, HRH3 | PTGDR2 32/4885CYP2C9 788/4885CYP2C19 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.